Search
Vaccines Treatment Options
A collection of 948 research studies where Vaccines is the interventional treatment. These studies are located in the United States. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
337 - 348 of 948
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants
Completed
This study is designed to evaluate the safety and tolerability of 20vPnC in healthy infants.
Gender:
ALL
Ages:
Between 42 days and 98 days
Trial Updated:
05/18/2023
Locations: Eclipse Clinical Research, Tucson, Arizona +96 locations
Conditions: Pneumococcal Disease
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Completed
This randomized phase II trial studies how well sipuleucel-T with or without tasquinimod works in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Tasquinimod may stop the growth of prostate cancer by blocking the growth of new blood vessels necessary for tumor growth. It is not yet known whether sipuleucel-T... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/25/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
A Cytomegalovirus-Directed Vaccine (CMV-alphaDC1) for Preventing Cytomegalovirus Infection or Reactivation in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Withdrawn
This phase Ib trial evaluates the safety and most effective dose of a cytomegalovirus (CMV) pp65 peptide-loaded alpha-type-1 polarized dendritic cell (CMV-alphaDC1) vaccination in patients who are undergoing an allogeneic hematopoietic stem cell transplant. CMV is an opportunistic infection that can occur or reactivate after allogeneic hematopoietic stem cell transplant as a result of immunosuppression. The CMV-alphaDC1 vaccine is made of white blood cells that have been exposed to molecules cal... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2023
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cytomegaloviral Infection, Hematopoietic and Lymphoid System Neoplasm
Gene Signatures of Influenza Vaccine Responses in Older Adults
Completed
The purpose of this research study is to better understand the immune response to the Adjuvanted Subunit flu vaccine (MF59) and the High Dose flu vaccine (HDFlu) in people 65 years of age and older. The research team will be studying why immune response diminishes as people get older in both men and women. The ultimate goal is to understand how flu immunity develops after vaccination. This information may lead to the development of more effective flu vaccines in the future.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
04/21/2023
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Influenza
The Influence of Chronic CMV Infection on Influenza Vaccine Responses
Completed
In this study we are trying to understand whether previous infection with a particular virus, namely cytomegalovirus (CMV), influences the ability of the immune system to respond to new infections or vaccinations with age.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
04/17/2023
Locations: Stanford University School of Medicine, Stanford, California
Conditions: Cytomegalovirus Infections, Influenza
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
Completed
The purpose of this study was to evaluate the reactogenicity, safety and immune response of a single intramuscular dose of the respiratory syncytial virus maternal (RSV MAT) vaccine in healthy non-pregnant girls 9-17 years of age (YOA) compared to non-pregnant adult women 18-49 YOA. The combined reduced-antigen-content diphtheria, tetanus and acellular pertussis (dTpa) vaccine was planned to be used as an active control for safety and reactogenicity evaluation.
Following a recommendation from t... Read More
Gender:
FEMALE
Ages:
Between 9 years and 49 years
Trial Updated:
04/06/2023
Locations: GSK Investigational Site, Miami, Florida +1 locations
Conditions: Respiratory Syncytial Virus Infections
A Phase I Study of WT1 or NY-ESO-1 Vaccine and Nivolumab For Recurrent Ovarian Cancer
Completed
The purpose of this study is to test the safety of a combination of an investigational WT1 vaccine and another drug called nivolumab. This is the first time that the WT1 vaccine and nivolumab are being used in combination. Also, to test the safety of a combination of an investigational NY-ESO-1 vaccine and another drug called nivolumab.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/06/2023
Locations: Memorial Sloan Kettering Cancer Center (All Protocol Activities), Basking Ridge, New Jersey +6 locations
A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine
Unknown
This clinical trial is to study the safety and tolerability of a recombinant herpes zoster vaccine (LZ901) and sponsored by Beijing Luzhu Biotechnology Co., Ltd. It is a phase I, randomized, double-blind, placebo-controlled, dose escalation study in healthy people aged 50 to 70 years inclusive. The study is to protect adults against shingles (herpes zoster / varicella zoster virus(VZV)). There will be about 66 participators who will receive two-dose injection at the upper arm.
LZ901 vaccine is... Read More
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
03/23/2023
Locations: Frontage Clinical Services, Inc., Secaucus, New Jersey
Conditions: Herpes Zoster, Vaccine-Preventable Diseases
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 222, Novartis Investigational Site, Chandler, Arizona +166 locations
Conditions: Influenza Virus
Adjuvanted Influenza Vaccination in U.S. Nursing Homes
Completed
This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/14/2023
Locations: Insight Therapeutics, LLC, Norfolk, Virginia
Conditions: Influenza, Influenza-like Illness
Recombinant Influenza Vaccination in U.S. Nursing Homes
Unknown
Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause hospitalization.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
03/14/2023
Locations: Insight Therapeutics, LLC, Norfolk, Virginia
Conditions: Influenza, Influenza -Like Illness, Influenza, Human
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
Completed
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
Gender:
ALL
Ages:
Between 12 months and 84 months
Trial Updated:
03/06/2023
Locations: Not set, San Diego, California +27 locations
Conditions: Influenza
337 - 348 of 948